Wayne also said this in 2017 when we first got approval in...

Wayne also said this in 2017 when we first got approval in India 
= Terrible sales result and no VascuCel or Cardiocel3D approval

Today’s approval is the result of Admedus working closely with Indian clinicians, health officials and key opinion leaders (KOLs) to determine demand for CardioCel, and to create productive long-term relationships focused on helping physicians heal Indian patients with heart disease. This pre-market assessment phase – which included Admedus participation at key scientific conferences – found strong interest from Indian KOLs who are eager to start using CardioCel as soon as possible.Admedus’ agreement with Syncronei Medical followed a comprehensive due diligence process to ensure CardioCel is effectively launched and properly positioned in this major emerging market. Syncronei Medical was awarded the distribution partnership based on their credibility and experience in the Indian regenerative technology and surgical sectors, coupled with an unparalleled ability to introduce CardioCel to India’s lucrative public and private medical tourism market segments which continue to grow impressively.1 via healthcare regulatory consultancy Fermish Clinical Technologies Pvt Ltd which handled the registration process and will hold the applicable licenses on behalf of Admedus. For personal use only “Today’s regulatory approval for CardioCel marks the first phase of our India market entry, and the acceleration of our emerging markets strategy,” added Paterson. “Our India pre-market assessment for VascuCel® and CardioCel 3D is now in the final stages, so in 2018 we plan to move up the value chain with the entire platform of ADAPT products in a massive market where we can scale for long-term success.”